In conclusion, aflibercept 5 + PRN intravitreal injection with PRP was safe and effective in treating patients with both PDR and DME, and it improved CFT better than in 3 + PRN (MA); however, BCVA, NV, and HE area, and VEGF, MCP-1, GFAP cytokines in aqueous aflibercept 3 + PRN group were not improved. This evidence concerns the gene CCL2 and hereditary elliptocytosis.